Q3 2018 Amphastar Pharmaceuticals Inc Earnings Call
שיחת ועידה Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Conference call or earnings call will be held on 08/11/2018 via an 800 number (toll-free). During the earnings conference call's session Amphastar Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Amphastar Pharmaceuticals Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, in 2014, we commenced sales of insulin active pharmaceutical ingredient, or insulin API, products. We currently manufacture and sell 18 products including Amphadase®, which we re-launched in the fourth quarter of 2015. Additionally, we are developing a portfolio of 12 generic abbreviated new drug applications, or ANDAs, three generic biosimilar and six proprietary injectable and inhalation product candidates. For the years ended December 31, 2015, 2014, and 2013, we recorded net revenues of $251.5 million, $210.5 million, and $229.7 million, respectively. We recorded a net loss of $2.8 million and $10.7 million for the years ended December 31, 2015 and 2014, respectively, and recorded net income of $11.9 million for the year ended December 31, 2013.קרא עוד שיחת ועידה